Interleukin 6, Recombinant, Mouse (IL-6)

Interleukin (IL)-6 is an important proinflammatory and immunoregulatory cytokine expressed by various cells.Interleukin-6 has been shown to inhibit the growth of early stage and to promote the proliferation of advanced stage melanoma cells in vitro. \n\nBiological Activity: Recombinant Murine IL-6 is fully biologically active when compared to standard. The ED50 determined by the dose-dependent induction of 7TD1 cell proliferation is 0.018ng/ml.\n\nAA Sequence:\nMFPTSQVRRG DFTEDTTPNR PVYTTSQVGG LITHVLWEIV EMRKELCNGN SDCMNNDDAL AENNLKLPEI QRNDGCYQTG YNQEICLLKI SSGLLEYHSY LEYMKNNLKD NKKDKARVLQ RDTETLIHIF NQEVKDLHKI VLPTPISNAL LTDKLESQKE WLRTKTIQFI LKSLEEFLKV TLRSTRQT\n\nStorage and Stability:\nLyophilized powder may be stored at -20 degrees C. Stable for 12 months at -20 degrees C. Reconstitute with 10mM HCl and a carrier protein (0.1% HSA or BSA). Aliquot to avoid repeated freezing and thawing. Store at -20 degrees C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer.

Prices direct from United States Biological

Quick response times

Exclusive Biosave savings/discounts

SPECIFICATIONS

Catalog Number

I8428-10C

Size

2ug

Form

Supplied as a lyophilized powder. Reconstitute with 10mM HCl to 0.1-1mg/ml, and a carrier protein (0.1% HSA or BSA).

Purity

>95% as determined by reducing and non-reducing SDS-PAGE.

References

1. Production of soluble human interleukin-6 in cytoplasm by fed-batch culture of recombinant E. coli. Biotechnol Prog (2005) 21:524-531. 2. Recombinant human interleukin-6 infusion during low-intensity exercise does not enhance whole body lipolysis or fat oxidation in humans. Am J Physiol Endocrinol Metab (2005) 289:E2-7. 3. Kaposi's sarcoma-associated herpesvirus-encoded viral interleukin-6 is secreted and modified differently than human interleukin-6: evidence for a unique autocrine signaling mechanism. J Biol Chem (2004) 279:51793-51803.\n4. Two novel somatic mutations in the human interleukin 6 promoter region in a patient with sporadic breast cancer. Eur J Immunogenet (2003) 30:397-400. 5. Cellular cholesterol depletion triggers shedding of the human interleukin-6 receptor by ADAM10 and ADAM17 (TACE).\nJ Biol Chem (2003) 278:38829-38839. 6. Effect of in situ expression of human interleukin-6 on antibody responses against Salmonella typhimurium antigens. FEMS Immunol Med Microbiol (2003) 37:135-145.